Under the deal, the contract development and manufacturing organisation (CDMO) will produce the as yet un-named product on a commercial scale at its facility in Scotland, UK.
According to Robbie Stewart, sales director at Encap, the product is now awaiting its final approval and will be launched “imminently”.
Speaking about the switch over from a fellow CDMO, Stewart also told Outsourcing-pharma.com that it was Encap’s long-term service capabilities that bagged the contract.
He said: “The other company had been involved with some of the development of the product, however the license holder switched to us because they wanted a long term commercial manufacturing partner.
“We have the capabilities to produce high volume in a liquid capsule product over a long period of time.”
When asked about the length of the agreement, Stewart added that there is no fixed-term, and that it could in theory run “indefinitely”.
On the lookout
CEO Stephen Brown told in-PharmaTechnologist that the Encap is now on the lookout for more partnerships, not only over licensed products, but also for clients in development phase. “We’re continually on the lookout,” he said.
Stewart added that the firm will put a special focus on adding to its recently upgraded high potency (HP) suite.
“We moved to the new facility in Scotland back in 2005 and expanded it to include a HP unit around 2009-10,” he said.
“The HP unit produces mainly two things – potent products like hormones, and other low dosage products, and oncology substances such as cytotoxic and cytostatic products.
“We now have six HP products produced in Scotland, and are looking to expand this over the next few years.”
He also said he sees a bright future for the liquid and semi-solid hot melt filled capsule specialist as the industry is still growing.
“There is an increasingly wide range of applications for liquid fill technology, and there has been big growth in liquid fill over the last five to ten years because it can solve a lot of problems like solubility, also work with clients looking for a controlled or targeted release formulation.”